These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 21091117)

  • 1. Immunotherapy of systemic sclerosis.
    Manno R; Boin F
    Immunotherapy; 2010 Nov; 2(6):863-78. PubMed ID: 21091117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
    Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
    Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
    Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
    Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.
    Fraticelli P; Gabrielli B; Pomponio G; Valentini G; Bosello S; Riboldi P; Gerosa M; Faggioli P; Giacomelli R; Del Papa N; Gerli R; Lunardi C; Bombardieri S; Malorni W; Corvetta A; Moroncini G; Gabrielli A;
    Arthritis Res Ther; 2014 Jul; 16(4):R144. PubMed ID: 25007944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment in systemic sclerosis: current status.
    Quillinan NP; Denton CP
    Curr Opin Rheumatol; 2009 Nov; 21(6):636-41. PubMed ID: 19726995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
    Volkmann ER; Tashkin DP
    Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
    Mendoza FA; Jiménez SA
    Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatments in systemic sclerosis.
    Asano Y
    J Dermatol; 2010 Jan; 37(1):54-70. PubMed ID: 20175840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
    Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
    Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis.
    van Laar JM; Farge D; Tyndall A
    Ann Rheum Dis; 2005 Oct; 64(10):1515. PubMed ID: 16162905
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in the treatment of systemic sclerosis.
    Bournia VK; Vlachoyiannopoulos PG; Selmi C; Moutsopoulos HM; Gershwin ME
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):176-200. PubMed ID: 19132559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cells: HSCT for systemic sclerosis--swallows and summers.
    Tyndall A
    Nat Rev Rheumatol; 2011 Sep; 7(11):624-6. PubMed ID: 21912430
    [No Abstract]   [Full Text] [Related]  

  • 19. Stem cell transplantation for systemic sclerosis.
    Bruera S; Sidanmat H; Molony DA; Mayes MD; Suarez-Almazor ME; Krause K; Lopez-Olivo MA
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011819. PubMed ID: 35904231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib].
    Kameda H
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):77-84. PubMed ID: 19404005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.